Obesity pipeline
Drugs
Every obesity program in this file, grouped by class. Open a drug for its studies and the sources behind each figure.
ClassNone selected
MechanismNone selected
All programs shown
94 of 94 programs shown
GLP-1 RA 17 drugs
- BeinaglutideCompany n/rStage n/rsubcutaneous1 studyGLP-1 RA
- BofanglutideGan & Lee PharmaceuticalsPhase 3subcutaneous8 studiesGLP-1 RA
- DapiglutideZealand PharmaPhase 2subcutaneous2 studiesGLP-1 RA
- DulaglutideCompany n/rPhase 3subcutaneous11 studiesGLP-1 RA
- EcnoglutideHangzhou Sciwind Biosciences CoPhase 3subcutaneous5 studiesGLP-1 RA
- Efsubaglutide AlfaShanghai Yinnuo Pharmaceutical Technology CoPhase 2/3subcutaneous5 studiesGLP-1 RA
- ExenatideAstraZenecaPhase 3subcutaneous15 studiesGLP-1 RA
- HDM1002Huadong MedicinePhase 3oral5 studiesGLP-1 RA
- LiraglutideSaxendaNovo NordiskApprovedsubcutaneous30 studiesGLP-1 RA
- LixisenatideSanofiPhase 3subcutaneous3 studiesGLP-1 RA
- LotiglipronPfizerPhase 2oral6 studiesGLP-1 RA
- MazdutideInnoventPhase 3subcutaneous20 studiesGLP-1 RA
- Oral SemaglutideNovo NordiskPhase 3oral5 studiesGLP-1 RA
- SemaglutideWegovyNovo NordiskApprovedsubcutaneous and oral37 studiesGLP-1 RA
- SupaglutideShanghai Yinnuo Pharmaceutical Technology Co.Phase 2/3subcutaneous5 studiesGLP-1 RA
- TaspoglutideRochePhase 3subcutaneous1 studyGLP-1 RA
- TG103CSPC Baike (Shandong) Biopharmaceutical CoPhase 3subcutaneous5 studiesGLP-1 RA
GLP-1/GIP 7 drugs
- BGM0504BrightGene Bio-Medical Technology CoPhase 3subcutaneous and oral8 studiesGLP-1/GIP
- CT-388RochePhase 3subcutaneous8 studiesGLP-1/GIP
- HDM1005Huadong MedicinePhase 3subcutaneous8 studiesGLP-1/GIP
- Oral VK2735Viking TherapeuticsPhase 3oral4 studiesGLP-1/GIP
- RibupatideFujian Shengdi Pharmaceutical CoPhase 3subcutaneous10 studiesGLP-1/GIP
- TirzepatideZepboundEli LillyApprovedsubcutaneous41 studiesGLP-1/GIP
- VK2735Viking TherapeuticsPhase 3once weekly, subcutaneous3 studiesGLP-1/GIP
GLP-1/glucagon 4 drugs
- CotadutideAstraZenecaPhase 1subcutaneous2 studiesGLP-1/glucagon
- EfinopegdutideMerckPhase 1subcutaneous1 studyGLP-1/glucagon
- PemvidutideAltimmunePhase 2subcutaneous1 studyGLP-1/glucagon
- SurvodutideBoehringer IngelheimPhase 3subcutaneous21 studiesGLP-1/glucagon
GIP/GLP-1/glucagon 2 drugs
- RetatrutideEli LillyPhase 3subcutaneous13 studiesGIP/GLP-1/glucagon
- UBT251The United Bio-Technology (Hengqin) CoPhase 3subcutaneous8 studiesGIP/GLP-1/glucagon
Amylin combo 1 drug
- Cagrilintide/semaglutideCagriSemaNovo NordiskFiledsubcutaneous21 studiesAmylin combo
Oral small molecule 7 drugs
- AleniglipronGasherbrum Bio, IncPhase 3oral8 studiesOral small molecule
- DanuglipronPfizerPhase 1oral2 studiesOral small molecule
- ElecoglipronAstraZenecaPhase 3oral4 studiesOral small molecule
- OrforglipronFoundayoEli LillyApprovedoral23 studiesOral small molecule
- SafiglipronShandong Suncadia Medicine CoPhase 3oral7 studiesOral small molecule
- TERN-601Terns, IncPhase 2oral1 studyOral small molecule
- VCT220Vincentage Pharma CoPhase 3oral6 studiesOral small molecule
GLP-1 conjugate 1 drug
- Maridebart CafraglutideAmgenPhase 3subcutaneous17 studiesGLP-1 conjugate
Amylin 6 drugs
- ABBV-295AbbViePhase 2subcutaneous4 studiesAmylin
- ACCG-2671Aconcagua Bio, IncPhase 1/2oral1 studyAmylin
- CagrilintideNovo NordiskPhase 3subcutaneous8 studiesAmylin
- EloralintideEli LillyPhase 3subcutaneous14 studiesAmylin
- PetrelintideRochePhase 3subcutaneous6 studiesAmylin
- PramlintideAstraZenecaPhase 2/3subcutaneous12 studiesAmylin
Myostatin/activin 3 drugs
- ApitegromabScholar RockPhase 2intravenous1 studyMyostatin/activin
- BimagrumabEli LillyPhase 2intravenous and subcutaneous3 studiesMyostatin/activin
- GaretosmabRegeneronPhase 2intravenous2 studiesMyostatin/activin
MC4R 1 drug
- SetmelanotideRhythmPhase 3subcutaneous15 studiesMC4R
CB1 2 drugs
- MonlunabantInversago PharmaPhase 2oral3 studiesCB1
- RimonabantSanofiPhase 3oral10 studiesCB1
Lipase inhibitor 1 drug
- OrlistatXenicalEmpros Pharma ABApprovedoral12 studiesLipase inhibitor
Opioid and antidepressant 1 drug
- Naltrexone And BupropionOrexigen Therapeutics, IncPhase 3daily12 studiesOpioid and antidepressant
Sympathomimetic combo 1 drug
- Phentermine And TopiramateVIVUSPhase 3oral12 studiesSympathomimetic combo
Monoamine reuptake 2 drugs
- SibutramineAbbottPhase 3oral8 studiesMonoamine reuptake
- TesofensineNeuroSearchPhase 2daily4 studiesMonoamine reuptake
SARM 1 drug
- EnobosarmVeru IncPhase 2oral2 studiesSARM
Class not reported 34 drugs
- AlbiglutideGSKPhase 3subcutaneous6 studiesClass not reported
- ARO-ALK7ArrowheadPhase 1/2subcutaneous1 studyClass not reported
- ASC30Ascletis Pharma (China) CoPhase 3oral and subcutaneous5 studiesClass not reported
- AZD6234AstraZenecaPhase 3subcutaneous6 studiesClass not reported
- BerobenatidePfizerPhase 3subcutaneous12 studiesClass not reported
- BrenipatideEli LillyPhase 1subcutaneous1 studyClass not reported
- CetilistatAlizymePhase 1Route n/r1 studyClass not reported
- CRB-913Corbus PharmaceuticalsPhase 1Route n/r1 studyClass not reported
- CT-868Carmot Therapeutics, IncPhase 2subcutaneous4 studiesClass not reported
- CT-996Carmot Australia First Pty LtdPhase 1oral1 studyClass not reported
- DA-1726NeuroBo Pharmaceuticals IncPhase 1subcutaneous1 studyClass not reported
- EfpeglenatideSanofiPhase 3subcutaneous5 studiesClass not reported
- Eloralintide And TirzepatideEloraTZPEli LillyPhase 3subcutaneous3 studiesClass not reported
- GUB014295AbbViePhase 1subcutaneous1 studyClass not reported
- HDM1702Huadong MedicinePhase 3once weekly, injection1 studyClass not reported
- HM15211HanmiPhase 1subcutaneous2 studiesClass not reported
- HS-20094RegeneronPhase 3subcutaneous7 studiesClass not reported
- LB54640RhythmPhase 2oral3 studiesClass not reported
- LoxenatideCompany n/rPhase 2/3injection1 studyClass not reported
- LY4086940Eli LillyPhase 2Route n/r2 studiesClass not reported
- MET-233IPfizerPhase 1/2every 4 weeks, injection2 studiesClass not reported
- NimacimabSkye BiosciencePhase 2injection1 studyClass not reported
- NNC0165-1875Novo NordiskPhase 2subcutaneous2 studiesClass not reported
- NNC0519-0130Novo NordiskPhase 2subcutaneous6 studiesClass not reported
- NoiiglutideHengruiPhase 3subcutaneous3 studiesClass not reported
- PF-07976016PfizerPhase 2oral2 studiesClass not reported
- RAY1225Guangdong Raynovent Biotech CoPhase 3subcutaneous4 studiesClass not reported
- SCO-940/CT-G32ScohiaPreclinicalRoute n/r0 studiesClass not reported
- TaldefgrobepBiohaven TherapeuticsPhase 2subcutaneous1 studyClass not reported
- TrevogrumabRegeneronPhase 2Route n/r0 studiesClass not reported
- VelneperitShionogiPhase 2oral3 studiesClass not reported
- VisepegenatidePegBio CoPhase 1/2subcutaneous1 studyClass not reported
- VRB-101Verdiva Bio Dev LimitedPhase 2oral3 studiesClass not reported
- ZenagamtideNovo NordiskPhase 3subcutaneous and oral6 studiesClass not reported
MetAP2 inhibitor 1 drug
- BeloranibZafgenPhase 3subcutaneous6 studiesMetAP2 inhibitor
Serotonin agonist 1 drug
- LorcaserinNovo NordiskPhase 1/2oral6 studiesSerotonin agonist
Small molecule 1 drug
- MDR-001MindRank AI LtdPhase 3oral4 studiesSmall molecule